Sinopec Rises 5.12% Amid Uptrend in COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme

On the 7th, the COVID-19 (plasma treatment/plasma therapeutics) theme showed a strong performance, rising 5.34% compared to the previous day, while Sinopex, a stock attracting attention as a related company, surged 5.12% compared to the previous day. Sinopex is known as a company specializing in touchscreen and mobile phone parts manufacturing and water treatment.

[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapeutics) theme

According to provisional data compiled at 11:53, foreigners are net selling 64,000 shares of Sinopex.

[Table] Net trading volume by foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Sinopex’s quant financial score is 28.5 points, ranking 6th in the quant financial ranking within the COVID-19 (plasma treatment/plasma therapeutics) related theme. This can be interpreted as Sinopex having relatively low investment attractiveness from a financial perspective. On the other hand, SMAC ranked 1st in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.